Apolipoprotein H/ApoH Antibody

Western blot shows lysates of rat liver tissue and mouse serum. PVDF membrane was probed with 0.25 µg/mL of Sheep Anti-Mouse/Rat Apolipoprotein H/ApoH Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6575) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Apolipoprotein H/ApoH at approximately 50-60 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

• Reactivity: Mu, Rt
• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Unconjugated
• Concentration: LYOPH

Apolipoprotein H/ApoH Antibody Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse Apolipoprotein H/ApoH
  Gly20-Cys345
  Accession # Q01339
• Specificity: Detects mouse and rat Apolipoprotein H/ApoH in Western blots and detects recombinant mouse Apolipoprotein H/ApoH in direct ELISAs. In direct ELISAs, approximately 40% cross-reactivity with recombinant human Apolipoprotein H/ApoH is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Gene: APOH
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.2 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Apolipoprotein H/ApoH Antibody

• Activated protein C-binding protein
• Anticardiolipin cofactor
• APC inhibitor
• APOH
• apo-H
• apolipoprotein H (beta-2-glycoprotein I)
• Apolipoprotein H
• B2G1
• B2GP1
• B2GPI
• Beta
• beta(2)GPI
• beta-2-glycoprotein 1
• Beta-2-glycoprotein I
• BG

Background

Apolipoprotein H (ApoH), also known as beta 2‑Glycoprotein I/ beta 2-GPI, is a variably glycosylated member of the complement control superfamily of proteins with a molecular weight of aproximately 50 kDa (1, 2). Mature mouse ApoH consists of four tandem Sushi/SCR repeats followed by one Sushi-like repeat (3, 4). Mature mouse ApoH shares 76% and 42% aa sequence identity with human and rat ApoH, respectively. Hepatocyte-derived ApoH binds directly to negatively charged phospholipids (5). It circulates as a component of lipoprotein particles and as a lipid-free serum protein (6). ApoH also associates with liposomes and apoptotic cell debris, thereby enabling their renal clearance via Megalin uptake (7, 8). Circulating levels of ApoH are postively correlated with triglyceride-rich lipoprotein (VLDL) components in type II diabetes (9). ApoH inhibits thrombosis by blocking the activation of Coagulation Factor XI but also shows procoagulant activity by inhibiting the activation of Protein C (10, 11). ApoH can be cleaved by Plasmin at Lys317‑Thr318, an action that is enhanced by heparin (12, 13). ApoH cleavage reduces its ability to bind phospholipids and inhibit Factor XI activation but confers the ability to bind Plasminogen (10, 12, 14). Cleaved ApoH also demonstrates antiangiogenic activity, whereas intact ApoH does not (14). The production of antibodies against ApoH is a hallmark of Antiphospholipid Syndrome (APS), an autoimmune disorder that leads to hypercoagulability and recurrent miscarriages (15). ApoH binds to the surface antigen of Hepatitis B Virus and is associated with the development of HBV-induced hepatocellular carcinoma (6, 16).

1. Crook, M.A. et al. (2010) Atherosclerosis 209:32.
2. Miyakis, S. et al. (2004) Thromb. Res. 114:335.
3. Nonaka, M. et al. (1992) Genomics 13:1082.
4. Lozier, J. et al. (1984) Proc. Natl. Acad. Sci. 81:3640.
5. Wurm, H. (1984) Int. J. Biochem. 16:511.
6. Mehdi, H. et al. (1994) J. Virol. 68:2415.
7. Chonn, A. et al. (1995) J. Biol. Chem. 270:25845.
8. Moestrup, S.K. et al. (1998) J. Clin. Invest. 102:902.
9. Castro, A. et al. (2010) Atherosclerosis 209:201.
10. Shi, T. et al. (2004) Proc. Natl. Acad. Sci. 101:3939.
11. Mori, T. et al. (1996) Thromb. Haemost. 75:49.
12. Hunt, J. et al. (1993) Proc. Natl. Acad. Sci. 90:2141.
13. Guerin, J. et al. (2002) J. Biol. Chem. 277:2644.
14. Sakai, T. et al. (2007) Am. J. Pathol. 171:1659.
15. Adams, M. (2008) Semin. Thromb. Haemost. 34:251.
16. Jing, X. et al. (2010) J. Cancer Res. Clin. Oncol. 16:1671.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Apolipoprotein H/ApoH Antibody (AF6575)(2)

Publications using AF6575

• Z. Oaks, A. Patel, N. Huang, G. Choudhary, T. Winans, T. Faludi et al. Cytosolic aldose metabolism contributes to progression from cirrhosis to hepatocarcinogenesis Nature Metabolism 1/19/2023 [PMID: 36658399]
• Gram Negative Bacterial Inflammation Ameliorated by the Plasma Protein Beta 2-Glycoprotein I Sci Rep, 2016-09-27;6(0):33656. 2016-09-27 [PMID: 27670000] (ELISA Development (Capture), Mouse)

Bioinformatics

• Gene Symbol: APOH
• Uniprot:
  • Q01339()